EUVIMEDEUVIMED entdecken
Crossref

Evaluation of the effect of vitreomacular interface disorders on anti-VEGF treatment in patients with diabetic macular edema in real life: MARMASIA study group report No. 10

Erdinç Bozkurt, Fatih Bilgehan Kaplan, Ecem Önder Tokuç, Aslan Aykut, Işılay Özsoy Saygın, Hatice Selen Kanar, Işıl Kutlutürk, Mehmet Orkun Sevik, Uğur Yayla, Erkan Çelik, Ayşe Demirciler Sönmez, Tugba Aydogan Gezginaslan und 10 weitere

International Ophthalmology · 2024

DOI: 10.1007/s10792-024-03251-1 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Ophthalmology, 2024. Verfasst von Erdinç Bozkurt und 21 weiteren Autor:innen. Beteiligte Einrichtung: Umraniye Education and Research Hospital, Department of Ophthalmology, FEBO, The University of Health Sciences, Istanbul, Turkey. drerdincbozkurt@hot…. Hauptthemen laut MEDLINE: Macular Edema, Diabetic Retinopathy, Angiogenesis Inhibitors, Visual Acuity. Die Arbeit nennt 26 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: The aim of this study is to investigate the effect of vitreomacular interface disorders (VMID) on treatment response in patients treated with anti-vascular endothelial growth factor (anti-VEGF) due to diabetic macular edema (DME). METHODS: Three hundred seventy-seven eyes of 239 patients in the MARMASIA Study Group who received intravitreal anti-VEGF treatment (IVT) due to DME were included in the study. The group 1 consisted of 44 eyes of the patients who had not received any treatment before, were followed up regularly for 24 months after at least a 3-month loading dose, and suffered from VMID such as epiretinal membrane, vitreomacular adhesion or traction, and lamellar hole. The group 2 consisted of 333 eyes of the patients without VMID. Best-corrected visual acuity (BCVA) and central macular thickness (CMT) of the patients at baseline, 3rd month, 6th month, 1st year and 2nd year follow-ups were measured. RESULTS: The mean age of the Groups 1 and 2 was 67.1 ± 11.3 and 61.9 ± 10.2 years, respectively. 61.3% of the group 1 and 58.8% of the group 2 were female (p > 0.05). The duration of diabetes was 19.2 ± 3.7 and 15.8 ± 3.2 years, respectively, and the number of follow-ups was 16.09 ± 4.68 and 12.06 ± 4.58, respectively in the groups (p < 0.001, 0.001, respectively). The number of IVT was 7.13 ± 2.71 and 7.20 ± 2.22, respectively in the groups 1 and 2 and no statistically significant difference was observed between them (p = 0.860). According to logMAR, BCVA values at baseline were 0.63 ± 0.24 and 0.59 ± 0.26 (p = 0.29), respectively, in the groups and the amount of change in BCVA at the end of the 2nd year was - 0.02 ± 0.48 in the group 1 and - 0.12 ± 0.48 in the group 2. It was observed as 0.48 (p = 0.13). Although the increase in BCVA was greater at all follow-ups in the group 2 compared to their initial examination, no significant difference was observed between the groups in terms of BCVA change. The CMT values of the groups at baseline were 442.5 ± 131.3 µm and 590.9 ± 170.6 µm, respectively (p = 0.03) The decrease in CMT after IVT was significantly greater in the group 2 at all follow-ups when compared to the first group (p < 0.05). CONCLUSION: While the presence of VMID in DME patients receiving IVT did not affect visual results, it negatively affected the anatomical response and macular edema morphology. The presence of VMID at baseline affected the success of IVT. It should be taken into consideration that VMID may resolve spontaneously or with IVT, and new cases of VMID may occur in patients during the treatment process.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Macular EdemaDiabetic RetinopathyAngiogenesis InhibitorsVisual AcuityIntravitreal InjectionsTomography, Optical CoherenceVascular Endothelial Growth Factor AHumansFemaleMaleMiddle AgedAgedFollow-Up StudiesMacula LuteaRetrospective StudiesRanibizumabBevacizumabVitreous BodyTreatment Outcome

Stichwörter der Autor:innen

Anti-VEGF treatmentCentral macular thicknessDiabetic macular edemaVitreomacular interface disorder

Substanzen

Angiogenesis InhibitorsVascular Endothelial Growth Factor ARanibizumabBevacizumab

Autor:innen und Institutionen

  • Umraniye Education and Research Hospital, Department of Ophthalmology, FEBO, The University of Health Sciences, Istanbul, Turkey. drerdincbozkurt@hotmail.com.
  • Department of Ophthalmology, Fatih Sultan Mehmet Training and Research Hospital, Health Sciences University, Istanbul, Turkey.
  • Department of Ophthalmology, Kocaeli University Faculty of Medicine, Kocaeli, Turkey.
  • Department of Ophthalmology, Marmara University Faculty of Medicine, Istanbul, Turkey.
  • Umraniye Education and Research Hospital, Department of Ophthalmology, FEBO, The University of Health Sciences, Istanbul, Turkey.
  • Kartal Dr. Lütfi Kırdar City Hospital, Department of Ophthalmology, Istanbul, Turkey.

Zitieren

APA

Bozkurt, E., Kaplan, F. B., Önder Tokuç, E., Aykut, A., Özsoy Saygın, I., Kanar, H. S., Kutlutürk, I., Sevik, M. O., Yayla, U., Çelik, E., Demirciler Sönmez, A., Aydogan Gezginaslan, T., Limon, U., Türkseven Kumral, E., Erçalık, N. Y., Aydın Öncü, Ö., Başaran Emengen, E., Özkaya, A., Açıkalın Öncel, B., …, & Karabaş, V. L. (2024). Evaluation of the effect of vitreomacular interface disorders on anti-VEGF treatment in patients with diabetic macular edema in real life: MARMASIA study group report No. 10. International Ophthalmology. https://doi.org/10.1007/s10792-024-03251-1

Vancouver

Bozkurt E, Kaplan FB, Önder Tokuç E, Aykut A, Özsoy Saygın I, Kanar HS, et al. Evaluation of the effect of vitreomacular interface disorders on anti-VEGF treatment in patients with diabetic macular edema in real life: MARMASIA study group report No. 10. International Ophthalmology. 2024. doi:10.1007/s10792-024-03251-1

BibTeX
@article{Bozkurt2024,
  author = {Bozkurt, Erdinç and Kaplan, Fatih Bilgehan and Önder Tokuç, Ecem and Aykut, Aslan and Özsoy Saygın, Işılay and Kanar, Hatice Selen and Kutlutürk, Işıl and Sevik, Mehmet Orkun and Yayla, Uğur and Çelik, Erkan and Demirciler Sönmez, Ayşe and Aydogan Gezginaslan, Tugba and Limon, Utku and Türkseven Kumral, Esra and Erçalık, Nimet Yeşim and Aydın Öncü, Özlem and Başaran Emengen, Ece and Özkaya, Abdullah and Açıkalın Öncel, Banu and Yenerel, Nursal Melda and Şahin, Özlem and Karabaş, Veysel Levent},
  title = {Evaluation of the effect of vitreomacular interface disorders on anti-VEGF treatment in patients with diabetic macular edema in real life: MARMASIA study group report No. 10},
  journal = {International Ophthalmology},
  year = {2024},
  doi = {10.1007/s10792-024-03251-1}
}
Kostenlos starten →